ABT
New target, same basic vibe
Bernstein SocGen just took a little scissors to Abbott Laboratories’ upside, lowering its price target to $110 from $125. But before you panic-scroll: the firm kept an Outperform rating on the stock, which is Wall Street’s way of saying, “We still like it, just maybe not that much.”
Why this matters
Abbott has been stuck in a weird spot lately — cheap-ish, popular, but under pressure. The stock was trading around $95 in the piece, roughly 23% below where it started the year, and just above its 52-week low. So when analysts start trimming targets, it’s not exactly a confidence parade.
The bigger Abbott mood swing
This isn’t a one-off haircut. Other firms have also nudged their targets lower recently, which suggests investors are still digesting slower growth expectations and the aftershocks from Abbott’s latest results and guidance reset. In other words, the numbers may be solid enough to avoid disaster, but not flashy enough to light the stock on fire.
Big picture
Abbott still has the kind of business mix that makes long-term investors lean in — medical devices, diagnostics, and a few growth engines that don’t require a miracle. But for now, the market is treating it like a good student who just got downgraded from an A to an A-.